HIT Consultant – Read More
The clinical trials industry has never had more tools, data, or innovation aimed at accelerating timelines. In fact, if you walk the floor of any industry event you’ll see “acceleration” everywhere. It’s in the messaging, the booths, the product demos, and the promises. From AI-driven feasibility models to precision targeting, digital recruitment strategies, and decentralized trial technologies, the system appears more advanced and faster than ever. Yet approximately 80–85% of clinical trials fail to meet enrollment timelines, and nearly one in five trials fails to enroll a single patient at a site (Tufts Center for the Study of Drug Development). Patient recruitment continues to be the leading cause of delays. This raises an uncomfortable but necessary question: if the industry has the capability to accelerate trials, are we actually solving the right problem?
When process outpaces patient reality
Over the past decade, progress has largely centered on operational efficiency: better targeting, broader digital reach, and more sophisticated data aggregation. While these advancements are meaningful, they primarily optimize processes—not patient experience. Clinical trials do not fail because we cannot find patients; they fail because patients cannot, or choose not to, participate. Up to 30% of participants drop out before completing a study (National Institutes of Health), and recruitment alone can account for nearly 30% of total clinical trial timelines (Applied Clinical Trials). Despite the language of “patient-centricity,” patients are still often treated as inputs rather than stakeholders. They are recruited into protocols they did not help shape, measured against endpoints that may not reflect what matters in their daily lives, and expected to navigate burdens that do not align with their realities. The result is predictable: high screen failure rates, slow enrollment, and poor retention.
Technology, for all its promise, cannot fix what design gets wrong. AI can identify patients faster, digital strategies can reach them more efficiently, and data platforms can generate increasingly precise insights. But none of these innovations address a fundamental truth: if a trial does not fit into a patient’s life—or a site’s capacity—the system will not perform. It is also a misconception that incorporating patient feedback and real-world insights will slow timelines or significantly increase costs. In reality, failing to do so is what drives delays, amendments, and inefficiencies downstream. Investing earlier in alignment is not a tradeoff—it is what enables both speed and success, often preventing far more costly setbacks later.
Bringing the patient into protocol design
Over the past decade, the number of procedures per protocol has increased by more than 50%, while inclusion and exclusion criteria can eliminate up to 70–90% of otherwise eligible patients (Tufts CSDD). From a scientific standpoint, this precision is necessary. From a patient standpoint, it can be overwhelming or simply unworkable. This is where the industry has an opportunity—but not yet a consistent practice. Patient panels, patient surveys, and real-world data inputs can provide early insight into feasibility, helping sponsors understand not just whether patients exist, but whether they can realistically participate. Structured patient burden assessments, evaluating travel, time commitment, procedural load, and lifestyle disruption, can identify friction points before a protocol is finalized. Importantly, none of this requires compromising scientific integrity or patient safety. In fact, better alignment with patient reality often strengthens both, by improving adherence, data quality, and overall trial execution.
This complexity extends beyond patients to caregivers, who are often essential to participation, particularly in rare disease, oncology, and chronic conditions. Caregivers coordinate schedules, manage logistics, and provide emotional and physical support, yet their burden is rarely accounted for in trial design. This omission matters, especially when more than 40% of patients cite logistical challenges such as travel, time commitment, and coordination as key barriers to participation (CISCRP). Incorporating caregiver perspectives through surveys, advisory panels, and qualitative research can surface constraints that would otherwise go unseen and unaddressed.
When endpoints miss the patient
Clinical endpoints are designed to satisfy regulatory and scientific requirements, but they do not always reflect outcomes that patients value, such as quality of life or day-to-day symptom relief. Regulators are increasingly acknowledging this gap through initiatives like the FDA’s Patient-Focused Drug Development program, which emphasizes the importance of incorporating patient experience data into clinical development. Still, in practice, the patient voice is often introduced after key decisions have already been made. Real-world data, patient-reported outcomes, and ongoing patient feedback loops can help bridge this gap, but only if they are embedded early enough to shape endpoints, not just validate them.
You can’t accelerate what sites can’t support
Sites are frequently cited as a bottleneck in trial execution, yet site burden assessments, which evaluate staffing constraints, competing studies, operational complexity, and follow-up capacity, are not consistently integrated into planning. Without understanding site realities, even the best recruitment and retention strategies are at risk. Just as patient feasibility must be assessed upfront, so too must site feasibility, not as a checkbox, but as a dynamic input into trial design and execution.
From optimizing for recruitment to designing for participation
Clinical trial success starts with embedding the patient and caregiver voice early and continuously, not as a validation step, but as a core design input. It means leveraging patient panels, surveys, and real-world data to inform protocol feasibility, incorporating patient burden assessments to reduce friction, and evolving endpoints to reflect outcomes that matter in real life, not just in clinical settings.
Rethinking how the ecosystem operates
Sites need support, not just referrals, through better coordination, faster follow-up mechanisms, and reduced administrative burden. Sponsors, CROs, and partners must operate less like siloed contributors and more like an integrated system, with shared accountability for enrollment and retention outcomes. This requires real-time feedback loops between recruitment, screening, and enrollment so that strategies can adapt quickly based on what is actually happening, not what was predicted. Retention, in particular, must be designed proactively through patient education, logistical support, and ongoing engagement, rather than treated as a downstream issue.
Ultimately, trials do not fall behind because the industry lacks innovation. They fall behind because the pace of accelerating processes has not kept up with optimizing for people. True acceleration is not about moving faster through a fragmented, misaligned system. It is about removing the friction that slows it down in the first place. And today, the greatest source of friction is the gap between how trials are designed and how patients and their caregivers actually live.
About Suzanne Harris
Over a 30+ year career, I’ve led marketing strategy for both early-stage ventures and Fortune 500 companies, driving revenue growth, building strong brand equity, and deepening stakeholder engagement. But in 2003, when my two babies were diagnosed with a rare disease, I was forced to navigate a system that dismissed my concerns while my children suffered.
That experience changed everything. I learned the true power of patient voices — how advocacy, storytelling, and compassion can transform healthcare. It also shaped my purpose: to ensure sponsors, CROs, and sites embrace patient-centricity in every clinical trial.
